Navigation Links
Endologix Responds to Alleged Patent Infringement
Date:10/13/2009

IRVINE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has conducted further evaluation of the patent infringement lawsuit filed against the company last week by Cook Medical, and of the patents asserted in the lawsuit. Based upon this evaluation, Endologix believes that the alleged infringement is without merit and the company intends to vigorously defend its position.

John McDermott, Endologix President and Chief Executive Officer, said, "We are pleased that our initial evaluation of these claims, which Cook Medical waited for years to assert, has already yielded support for numerous promising defenses."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the claims of alleged infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                           INVESTOR CONTACTS:
    ----------------                           ------------------
    Endologix, Inc.                            The Ruth Group
    John McDermott, CEO                        Nick Laudico (646) 536-7030
    (949) 595-7200                             Zack Kubow (646) 536-7020
    www.endologix.com

SOURCE Endologix, Inc.


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. EPSScentral Responds to Pandemic Alert
3. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
4. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. Roche responds to announcement of IDEAL hepatitis C trial results
7. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
8. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
9. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
10. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
11. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Varian Medical Systems (NYSE: ... the second quarter of fiscal year 2017 following the close ... release will be followed by a teleconference available to all ... a link to the conference call webcast will be available ... the teleconference call and replay: ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... , March 29, 2017  Designers of primary cell ... solution size by 50% and extend battery life with ... management integrated circuit (PMIC) from Maxim Integrated Products, Inc. ... a low input voltage of just 0.7V for new ... Silver Oxide, as well as the more common Alkaline ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... An inventor from Raynham, Mass., knows ... in conjunction with my braces always rubbed against the inside of my cheeks, ... this problem." The O.B.S. was the result of his brainstorming. , This patent-pending ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... in many scientific laboratories. The assembly protocols involve many repetitive steps and often ... for automation, which enables the high-throughput needed, and results in a lower error ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... CA (PRWEB) , ... March 29, 2017 , ... Hamlin ... Northridge , is now offering laser dental treatments. Dental lasers are safe and effective ... dentistry expands patients’ options and can improve the overall quality of care. , Dr. ...
Breaking Medicine News(10 mins):